SCHEMBL684028

SCHEMBL684028

Cn1c(=O)c2c(ncn2CN2CCN(c3ccc(C(F)(F)F)cc3)CC2)n(C)c1=O

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.58
HTR6 P50406 1/20 0.58
RAB9A P51151 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.53
ABCC8 Q09428 1/20 0.51
KCNJ11 Q14654 1/20 0.51
RXFP1 Q9HBX9 3/20 0.51
MAPT P10636 2/20 0.51
ADORA2B P29275 6/20 0.47
MAPK1 P28482 2/20 0.47
HTR1A P08908 2/20 0.46
CHRM1 P11229 2/20 0.46
DRD2 P14416 2/20 0.46
ADRA1D P25100 2/20 0.46
ADRA1A P35348 2/20 0.46
ADRA1B P35368 2/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL684362 0.88 RAB9A (0.71) HTR7HTR6RAB9AL3MBTL1RXFP1
SCHEMBL683612 0.88 HTR7 (0.57) HTR7HTR6RAB9AL3MBTL1RXFP1
SCHEMBL682813 0.87 HTR7 (0.62) HTR7HTR6RAB9AL3MBTL1RXFP1
SCHEMBL682817 0.86 LMNA (0.62) HTR7HTR6RAB9AL3MBTL1RXFP1
SCHEMBL683655 0.86 HTR7 (0.77) HTR7HTR6RAB9AL3MBTL1RXFP1
SCHEMBL683604 0.84 RXFP1 (0.62) HTR7HTR6RAB9AL3MBTL1RXFP1
SCHEMBL684041 0.83 HTR7 (0.58) HTR7HTR6RAB9AL3MBTL1RXFP1
SCHEMBL683998 0.82 HTR7 (0.57) HTR7HTR6RAB9AL3MBTL1RXFP1
SCHEMBL684027 0.81 SMN1; SMN2 (0.60) HTR7HTR6RAB9AL3MBTL1RXFP1
SCHEMBL683995 0.79 MAPK1 (0.72) HTR7HTR6L3MBTL1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF HTR7 1398/4885HTR6 683/4885RAB9A 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.